References
- McQuay H. Opioids in pain management. Lancet. 1999;353(9171):2229–2232.
- Sunshine A, Olson NZ, Colon A, et al. Analgesic efficacy of controlled-release oxycodone in postoperative pain. J Clin Pharmacol. 1996;3:595–603.
- Gammaitoni AR, Galer BS, Bulloch S, et al. Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain. J Clin Pharmacol. 2003;43(3):296–304.
- Minkowitz HS, Rathmell JP, Vallow S, et al. Efficacy and safety of the fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery. Pain Med. 2007;8(8):657–668.
- Gaskell H, Derry S, Moore RA, et al. Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;(3):CD002763.
- Webster LR. The question of opioid euphoria. Drug Discovery & Development, 2009. [ cited 2 May 2013]. Available from: http://www.dddmag.com/Article-The-Question-of-Opioid-Euphoria-073009.aspx
- Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13–20.
- Smith SM, Dart RC, Katz NP, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287–2296.
- Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: summary of national findings. Rockville (MD): US Department of Health and Human Services; 2012. [ cited 2014 Nov 11]. Available from: http://www.samhsa.gov/data/sites/default/files/Revised2k11NSDUHSummNatFindings/Revised2k11NSDUHSummNatFindings/NSDUHresults2011.htm.
- Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: national estimates of drug-related emergency department visits. Rockville (MD): US Department of Health and Human Services; 2013. [ cited 2014 Dec 4].]. [ Available from: http://www.samhsa.gov/data/sites/default/files/DAWN2k11ED/DAWN2k11ED/DAWN2k11ED.pdf
- Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(3):241–248.
- Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: summary of national findings. Rockville (MD): US Department of Health and Human Services; 2014. [ cited 2014 Oct 4]. Available from: www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf.
- De Maeyer J, Vanderplasschen W, Broekaert E. Quality of life among opiate-dependent individuals: a review of the literature. Int J Drug Policy. 2010;21(5):364–380.
- Hogan DM. Annotation: the psychological development and welfare of children of opiate and cocaine users: review and research needs. J Child Psychol Psychiatry. 1998;39(5):609–620.
- Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657–667.
- Hansen RN, Oster G, Edelsberg J, et al. Economic costs of nonmedical use of prescription opioids. Clin J Pain. 2011;27(3):194–202.
- McCabe SE, West BT, Teter CJ, et al. Medical and nonmedical use of prescription opioids among high school seniors in the United States. Arch Pediatr Adolesc Med. 2012;166(9):797–802.
- Brands B, Blake J, Sproule B, et al. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004;73(2):199–207.
- Sim MG, Hulse GK, Khong E. Acute pain and opioid seeking behaviour. Aust Fam Physician. 2014;33(12):1009–1012.
- Cicero TJ, Kurtz SP, Surratt HL, et al. Multiple determinants of specific modes of prescription opioid diversion. J Drug Issues. 2011;41(2):283–304.
- Jones CM, Paulozzi LJ, Mack KA. Sources of prescription opioid pain relievers by frequency of past-year nonmedical use United States, 2008-2011. JAMA Intern Med. 2014;174(5):802–803.
- Passik SD. Tamper-resistant opioid formulations in the treatment of acute pain. Adv Ther. 2014;31(3):264–275.
- Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8:29.
- Vietri J, Joshi AV, Barsdorf AI, et al. Prescription opioid abuse and tampering in the United States: results of a self-report survey. Pain Med. 2014;15(12):2064–2074.
- IMS Health. Top 25 medicines by dispensed prescriptions (U.S.), 2013. [ cited 2013 Jun 27]. Available from: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press%20Room/2012_U.S/Top_25_Medicines_Dispensed_Prescriptions_U.S.pdf.
- Radnovich R, Chapman CR, Gudin JA, et al. Acute pain: effective management requires comprehensive assessment. Postgrad Med. 2014;126(4):59–72.
- Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research, 2012. [ cited 2013 Aug 12]. Available from: http://www.iom.edu/~/media/Files/Report%20Files/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research/Pain%20Research%202011%20Report%20Brief.pdf.
- Bates C, Laciak R, Southwick A, et al. Overprescription of postoperative narcotics: a look at postoperative pain medication delivery, consumption and disposal in urological practice. J Urol. 2011;185(2):551–555.
- Rodgers J, Cunningham K, Fitzgerald K, et al. Opioid consumption following outpatient upper extremity surgery. J Hand Surg Am. 2012;37(4):645–650.
- Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487–1492.
- Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician. 2014;17(2):E119–E28.
- Throckmorton DC. The science of abuse-deterrence – progress toward creating safer opioids. FDA Voice, 2013. [ cited 2014 Feb 18]. Available from: http://blogs.fda.gov/fdavoice/index.php/2013/04/the-science-of-abuse-deterrence-progress-toward-creating-safer-opioids/.
- Fenton JJ, Jerant AF, Bertakis KD, et al. The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. Arch Intern Med. 2012;172(5):405–411.
- Centers for Disease Control and Prevention (CDC). Law: prescription limits, 2012. [ cited 2015 Jan 2]. Available from: http://www.cdc.gov/HomeandRecreationalSafety/Poisoning/laws/rx_limits.html.
- US Drug Enforcement Administration. DEA history. [ cited 2015 Jan 10]. Available from: http://www.dea.gov/about/history.shtml.
- US Department of Justice and Drug Enforcement Administration. Drugs of Abuse: A DEA Resource Guide, 2011. [ cited 2014 Nov 5]. Available from: http://www.justice.gov/dea/pr/multimedia-library/publications/drug_of_abuse.pdf.
- US Food and Drug Administration. FDA introduces new safety measures for extended-release and long-acting opioid medications, 2012. [ cited 2014 May 9]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm310870.htm.
- US Food and Drug Administration. Questions and answers: FDA approves a risk evaluation and mitigation strategy (REMS) for extended-release and long-acting (ER/LA) opioid analgesics, 2013. [ Last accessed 2014 Jan 27]. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm309742.htm.
- US Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research (CDER). Abuse-Deterrent Opioids–Evaluation and Labeling: Guidance for Industry, 2015. [ cited 2015 Apr 1]. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf.
- American Academy of Pain Medicine. American Academy of Pain Medicine comments on rescheduling hydrocodone: patient and public health considerations, 2013. [ cited 2015 Jan 2]. Available from: http://www.painmed.org/press/position-statements/.
- US Department of Justice and Drug Enforcement Administration. Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II, 2014. [ Last acce 6 October 2014]. Available at: https://www.federalregister.gov/articles/2014/08/22/2014-19922/schedules-of-controlled-substances-rescheduling-of-hydrocodone-combination-products-from-schedule.
- US Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS), 2015. [ cited 2015 June 19]. Available from: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm111350.htm.
- US Food and Drug Administration. FDA approves shared system REMS for TIRF products, 2011. [ cited 2015 Jan 10]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm285345.htm.
- TIRF REMS Access. Welcome to the TIRF REMS Access education program for prescribers and pharmacists. [ cited 2015 Mar 18]. Available from: https://www.tirfremsaccess.com/TirfUI/rems/education.action.
- Passik SD, Hays L, Eisner N, et al. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5–13.
- Moorman-Li R, Motycka CA, Inge LD, et al. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T. 2012;37(7):412–418.
- Prescription Drug Monitoring Program Training & Technical Assistance Center. Drug schedules monitored. [ cited 2014 Feb 18]. Available from: http://www.pdmpassist.org/content/drug-schedules-monitored.
- Prescription Drug Monitoring Program Training & Technical Assistance Center. Status of prescription drug monitoring programs (PDMPs), 2014. [ cited 2015 Jan 28]. Available from: www.pdmpassist.org/pdf/PDMPProgramStatus2014.pdf.
- Baehren DF, Marco CA, Droz DE, et al. A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med. 2010;56(1):19–23.
- Chakravarthy B, Shah S, Lotfipour S. Prescription drug monitoring programs and other interventions to combat prescription opioid abuse. West J Emerg Med. 2012;13(5):422–425.
- Paulozzi LJ, Stier DD. Prescription drug laws, drug overdoses, and drug sales in New York and Pennsylvania. J Public Health Policy. 2010;31(4):422–432.
- Tudor CG. Supplemental guidance related to improving drug utilization review controls in part D. Baltimore (MD): Centers for Medicare & Medicaid Services; 2012. [ cited 2014 Nov 23]. Available from: http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/HPMSSupplementalGuidanceRelated-toImprovingDURcontrols.pdf.
- Gonzalez AMIII, Kolbasovsky A. Impact of a managed controlled-opioid prescription monitoring program on care coordination. Am J Manag Care. 2012;18(9):516–524.
- Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain. 2007;23(2):103–118.
- American Academy of Pain Medicine. The Evidence Against Methadone as a “Preferred” Analgesic: A Position Statement From the American Academy of Pain Medicine, 2014. [ cited 2014 Dec 31]. Available from: http://www.painmed.org/files/the-evidence-against-methadone-as-a-preferred-analgesic.pdf.
- Huskamp HA, Keating NL. The new medicare drug benefit: formularies and their potential effects on access to medications. J Gen Intern Med. 2005;20(7):662–665.
- Consumer Reports® Health Best Buy Drugs™. Using Opioids to Treat Chronic Pain: Comparing Efficacy, Safety, and Price, 2012. [ cited 2015 Jan 5]. Available from: www.consumerreports.org/health/resources/pdf/best-buy-drugs/OpioidsFINAL-April2008.pdf.
- Centers for Disease Control and Prevention (CDC). Vital signs: risk for overdose from methadone used for pain relief—united States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2012;61(26):493–497.
- Katz NP, Birnbaum H, Brennan MJ, et al. Prescription opioid abuse: challenges and opportunities for payers. Am J Manag Care. 2013;19(4):295–302.
- Adams S. Painkiller abuse spurs search for a safer opioid therapy. Bloomberg News, 2013. [ cited 2014 Nov 17]. Available from: http://www.bloomberg.com/news/2013-07-02/pankiller-abuse-spurs-search-for-a-safer-opioid-therapy.html.
- Hysingla ER [package insert]. Stamford (CT): Purdue Pharma LP; 2014
- EXALGO [package insert]. Hazelwood (MO): Mallinckrodt Pharmaceuticals; 2014
- EMBEDA [package insert]. New York (NY): Pfizer Inc; 2014
- XARTEMIS XR [package insert]. Hazelwood (MO): Mallinckrodt Pharmaceuticals; 2014
- OxyContin [package insert]. Stamford (CT): Purdue Pharma LP; 2014
- OXECTA [package insert]. New York (NY): Pfizer Inc; 2014
- TARGINIQ ER [package insert]. Stamford (CT): Purdue Pharma LP; 2014
- OPANA ER [package insert]. Malvern (PA): Endo Pharmaceuticals Inc; 2014
- NUCYNTA ER [package insert]. Titusville (NJ): Janssen Pharmaceuticals, Inc; 2014
- Pande P, Hines J, Brogan A. Tamper-resistant properties of once-daily hydromorphone ER (OROS hydromorphone). J Pain. 2011;12(4 suppl):P58.
- Morton T, Kostenbader K, Montgomery J, et al. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial. Postgrad Med. 2014;126(4):20–32.
- Alexander L, Mannion RO, Weingarten B, et al. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend. 2014;138:1–6.
- King Pharmaceuticals, Inc. Statement on voluntary recall of Embeda® extended release capsules CII [press release], 2011. [ cited 2014 Jan 20]. Available from: http://www.pfizer.com/files/news/embeda_recall_031611.pdf.
- Pfizer Inc. FDA approves abuse deterrent labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules CII [press release], 2014. [ cited 2015 Jan 6]. Available from: http://www.pfizer.com/news/press-release/press-release-detail/fda_approves_abuse_deterrent_labeling_for_embeda_morphine_sulfate_and_naltrexone_hydrochloride_extended_release_er_capsules_cii.
- Webster L, St Marie B, McCarberg B, et al. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. J Opioid Manag. 2011;7(3):235–245.
- Stanos SP, Bruckenthal P, Barkin RL. Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clin Proc. 2012;87(7):683–694.
- Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23(8):648–660.
- Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm. 2013;39(5):611–624.
- Webster LR, Rolleri RL, Pixton GC, et al. Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users. Subst Abuse Rehabil. 2012;3:101–113.
- Euro-Celtique SA. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent. US7144587 (2006)
- Comer SD, Zacny JP, Dworkin RH, et al. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain. 2012;153(12):2315–2324.
- Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351–358.
- Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14(10):1122–1130.
- Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187–189.
- Vosburg SK, Jones JD, Manubay JM, et al. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126(1–2):206–215.
- Vosburg SK, Jones JD, Manubay JM, et al. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Addiction. 2013;108(6):1095–1106.
- McCarberg BH. Pain management in primary care: strategies to mitigate opioid misuse, abuse, and diversion. Postgrad Med. 2011;123(2):119–130.
- Reidenberg MM, Willis O. Prosecution of physicians for prescribing opioids to patients. Clin Pharmacol Ther. 2007;81(6): 903–906.
- Egbert LD, Battit GE, Welch CE, et al. Reduction of postoperative pain by encouragement and instruction of patients: a study of doctor-patient rapport. N Engl J Med. 1964;270:825–827.
- Wilsey BL, Fishman SM, Tsodikov A, et al. Psychological comorbidities predicting prescription opioid abuse among patients in chronic pain presenting to the emergency department. Pain Med. 2008;9(8):1107–1117.
- Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46.
- Butler SF, Fernandez K, Benoit C, et al. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360–372.
- Passik SD, Squire P. Current risk assessment and management paradigms: snapshots in the life of the pain specialist. Pain Med. 2009;10(suppl 2):S101–S14.
- Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–442.
- Wu SM, Compton P, Bolus R, et al. The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage. 2006;32(4):342–351.
- Saffier K, Colombo C, Brown D, et al. Addiction severity index in a chronic pain sample receiving opioid therapy. J Subst Abuse Treat. 2007;33(3):303–311.
- Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1–2):144–156.
- Skinner HA. The drug abuse screening test. Addict Behav. 1982;7(4):363–371.
- Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130.
- Dowling LS, Gatchel RJ, Adams LL, et al. An evaluation of the predictive validity of the Pain Medication Questionnaire with a heterogeneous group of patients with chronic pain. J Opioid Manag. 2007;3(5):257–266.
- Knisely JS, Wunsch MJ, Cropsey KL, et al. Prescription Opioid Misuse Index: a brief questionnaire to assess misuse. J Subst Abuse Treat. 2008;35(4):380–386.
- Coambs RB, Jarry JL, Santhiapillai AC, et al. The SISAP: a new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain with the general practice. Pain Res Manag. 1996;1(3):155–162.
- Passik SD, Kirsh KL. Opioid therapy in patients with a history of substance abuse. CNS Drugs. 2004;18(1):13–25.
- Moore TM, Jones T, Browder JH, et al. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med. 2009;10(8):1426–1433.
- Clarke TK, Ambrose-Lanci L, Ferraro TN, et al. Genetic association analyses of PDYN polymorphisms with heroin and cocaine addiction. Genes Brain Behav. 2012;11(4):415–423.
- Katz J, Seltzer Z. Transition from acute to chronic postsurgical pain: risk factors and protective factors. Expert Rev Neurother. 2009;9(5):723–744.
- Sentürk M, Ozcan PE, Talu GK, et al. The effects of three different analgesia techniques on long-term postthoracotomy pain. Anesth Analg. 2002;94(1):11–15.
- Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2008;9(4):444–459.
- Gudin JA, Mogali S, Jones JD, et al. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013;125(4):115–130.
- American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report. Anesthesiology. 2012;116(2):248–273.
- The National Pharmaceutical Council and Joint Commission on Accreditation of Healthcare Organizations. Pain: Current Understanding of Assessment, Management and Treatments, 2001. [ cited 2013 Oct 16]. Available from: http://www.npcnow.org/system/files/research/download/Pain-Current-Understanding-of-Assessment-Management-and-Treatments.pdf.
- Peters CL, Shirley B, Erickson J. The effect of a new multimodal perioperative anesthetic regimen on postoperative pain, side effects, rehabilitation, and length of hospital stay after total joint arthroplasty. J Arthroplasty. 2006;21(6 suppl 2):132–138.
- Philip BK, Reese PR, Burch SP. The economic impact of opioids on postoperative pain management. J Clin Anesth. 2002;14(5):354–364.
- Hebl JR, Dilger JA, Byer DE, et al. A pre-emptive multimodal pathway featuring peripheral nerve block improves perioperative outcomes after major orthopedic surgery. Reg Anesth Pain Med. 2008;33(6):510–517.
- Wu JW, Wong YC. Elective unilateral total knee replacement using continuous femoral nerve blockade versus conventional patient-controlled analgesia: perioperative patient management based on a multidisciplinary pathway. Hong Kong Med J. 2014;20(1):45–51.
- Savage S, Covington EC, Gilson AM, et al. for the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Public Policy Statement on the Rights and Responsibilities of Healthcare Professionals in the Use of Opioids for the Treatment of Pain, 2004. [ cited 2015 May 5]. Available from: http://www.asam.org/advocacy/find-a-policy-statement/view-policy-statement/public-policy-statements/2011/12/15/rights-and-responsibilities-of-health-care-professionals-in-the-use-of-opioids-for-the-treatment-of-pain.
- Thorson D, Biewen P, Bonte B, et al. Institute for Clinical Systems Improvement. Acute Pain Assessment and Opioid Prescribing Protocol, 2014. [ cited 2015 May 5]. Available from: https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_pain_guidelines/opioids/.
- Vadivelu N, Singh-Gill H, Kodumudi G, et al. Practical guide to the management of acute and chronic pain in the presence of drug tolerance for the healthcare practitioner. Ochsner J. 2014;14(3):426–433.